Mitomed Pharma develops next‑generation dual‑specificity cancer therapeutics that selectively enter tumor cells and disrupt a mitochondrial protein‑protein interaction protecting cells from oxidative stress. By targeting a previously unknown vulnerability in iron acquisition and reactive oxygen species regulation, their systemically administered drugs aim to induce cancer cell death with minimal side effects, and can be used alone or alongside existing treatments such as chemotherapy or immunotherapy.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer cells rely on a mitochondrial mechanism that regulates iron acquisition and protects against oxidative stress, allowing them to proliferate despite high metabolic demands. Existing therapies often become ineffective against refractory tumors and cause severe side effects.
Solution
Mitomed Pharma creates dual‑specificity small‑molecule therapeutics that are administered systemically but selectively enter tumor cells. Once inside, the compounds localize to mitochondria and disrupt a critical protein‑protein interaction that shields cancer cells from oxidative damage. This targeted disruption triggers cell death by exploiting the cancer’s dependence on iron and reactive oxygen species management. The approach is designed to be minimally toxic, showing no adverse effects in animal studies, and can be combined with standard chemotherapy or immunotherapy to enhance treatment outcomes.
Target Audience
Primary customers are oncology pharmaceutical developers and clinical research organizations seeking novel, low‑toxicity agents for treating refractory solid tumors.
Features
- Systemic delivery with tumor‑cell selective uptake to limit exposure to healthy tissue
- Mitochondria‑targeted mechanism that interferes with iron acquisition and ROS protection pathways
- Dual‑specificity design that blocks a previously unexploited protein‑protein interaction essential for cancer cell survival
- Demonstrated lack of observable side effects in preclinical animal models
- Compatibility for use as monotherapy or in combination with existing chemotherapy and immunotherapy regimens